Insider · CIK 0001510224
James Joseph Martin
Files at COCP (Cocrystal Pharma, Inc.). First filing -, latest -.
In brief
James Joseph Martin files SEC Form 4 as CEO and CFO at COCP (Cocrystal Pharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James Joseph Martin has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | COCP Cocrystal Pharma, Inc. | AGrant or award Stock Options (Right to Buy)derivative | +49,229 | $0.00 | $0 | 49,229 | Jan 13, 2026 |
| Oct 28, 2025 | COCP Cocrystal Pharma, Inc. | AGrant or award Common Stock | +3,598 | $1.39 | $5,001 | 44,167 | Oct 30, 2025 |
| Oct 28, 2025 | COCP Cocrystal Pharma, Inc. | AGrant or award Warrantsderivative | +7,196 | $1.39 | $10k | 7,196 | Oct 30, 2025 |
| Oct 9, 2024 | COCP Cocrystal Pharma, Inc. | AGrant or award Common Stock | +40,000 | - | - | 40,569 | Oct 11, 2024 |
Questions about James Joseph Martin
Answered from the filings on this page, as of the latest one.
Is James Joseph Martin buying or selling?
James Joseph Martin has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James Joseph Martin's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James Joseph Martin has 0.
Where does James Joseph Martin file Form 4?
James Joseph Martin has filed Form 4 at COCP (Cocrystal Pharma, Inc.) as Co-CEO and CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.